Importantly, in clinical HCC samples, lenvatinib-sensitive patients showed lower LAPTM5 levels than LR patients, and recurrent patients after surgery had higher LAPTM5 expressions than non-recurrent ones. The gene discussed is LAPTM5; the disease is hepatocellular carcinoma.